Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study.

@article{Pagani2000EpidoxorubicinAD,
  title={Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study.},
  author={Olivia Pagani and Christiana Sessa and Franco Nole' and Diana Crivellari and Davide Lombardi and Beat Thuerlimann and Dagmar Hess and Markus M. Borner and Jacqui Bauer and Giovanni Martinelli and Rossella Graffeo and Massimo Zucchetti and Maurizio D'Incalci and Aron Goldhirsch},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2000},
  volume={11 8},
  pages={
          985-91
        }
}
BACKGROUND The combination of anthracyclines and taxanes is currently considered the first choice chemotherapy in advanced breast cancer (ABC) and considerable emphasis has been placed on programs exploring the safest and most efficient way to integrate these classes of drugs in both the metastatic and, more recently, the adjuvant setting. We report here the overall results of the combination of epidoxorubicin (E) 90 mg/m2 and docetaxel (D) 75 mg/m2 as first-line chemotherapy in ABC. PATIENTS… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 32 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 32 REFERENCES

Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer.

  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 1999
VIEW 3 EXCERPTS

Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1999

Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1999

Dieras V . Gruia G et al . Dose - finding study of docetaxel and doxorubicin in first - line treatment of patients with metastatic breast cancer

JL Misset
  • Ann Oncol
  • 1999

Escalating doses of docetaxel and epirubicin as first - line therapy for metastatic breast cancer . A phase I — II study of the National Cancer Institute of Canada Clinical Trials Group

ME Trudeau, M Crump, J Latreille
  • Proc Am Soc Clin Oncol
  • 1999

Ozisik Y et al . Combination of docetaxel and do . xo - rubicin as first - line chemotherapy in metastatic breast cancer

E Baltali
  • 9 th Anticancer Congress
  • 1999